NASDAQ: CORTCorcept Therapeutics Inc Stock
$58.00+1.50 (+2.65%)
Updated Mar 19, 2025
CORT Price
$58.00
Fair Value Price
$81.53
Market Cap
$6.12B
52 Week Low
$20.84
52 Week High
$75.00
P/E
42.96x
P/B
9x
P/S
7.71x
PEG
0.83x
Dividend Yield
N/A
Revenue
$675.04M
Earnings
$139.73M
Gross Margin
98.4%
Operating Margin
20.07%
Profit Margin
20.7%
Debt to Equity
0.24
Operating Cash Flow
$198M
Beta
0.86
Next Earnings
Apr 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CORT Overview
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CORT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CORT
Ranked#55 of 481
Ranked#55 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.25 | A | |
| $142.07 | A | |
| $1.55 | A |
Be the first to know about important CORT news, forecast changes, insider trades & much more!
CORT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CORT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CORT ($58.00) is undervalued by 28.86% relative to our estimate of its Fair Value price of $81.53 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CORT ($58.00) is significantly undervalued by 28.86% relative to our estimate of its Fair Value price of $81.53 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CORT ($58.00) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CORT due diligence checks available for Premium users.
Valuation
CORT fair value
Fair Value of CORT stock based on Discounted Cash Flow (DCF)
Price
$58.00
Fair Value
$81.53
Undervalued by
28.86%
CORT ($58.00) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CORT ($58.00) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CORT ($58.00) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CORT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
42.96x
Industry
-113.22x
Market
31.13x
CORT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CORT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
CORT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9x
Industry
4.75x
CORT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CORT price to earnings growth (PEG)
For valuing profitable companies with growth potential
CORT is good value based... subscribe to Premium to read more.
PEG Value Valuation
CORT's financial health
Profit margin
Revenue
$181.9M
Net Income
$30.4M
Profit Margin
16.7%
CORT's Earnings (EBIT) of $135.48M... subscribe to Premium to read more.
Interest Coverage Financials
CORT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$840.6M
Liabilities
$161.0M
Debt to equity
0.24
CORT's short-term assets ($471.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CORT's short-term assets ($471.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CORT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CORT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$59.3M
Investing
-$64.4M
Financing
-$4.6M
CORT's operating cash flow ($198.07M)... subscribe to Premium to read more.
Debt Coverage Financials
CORT vs Biotech Stocks
Corcept Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.